These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18669440)

  • 1. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate.
    Prins RM; Cloughesy TF; Liau LM
    N Engl J Med; 2008 Jul; 359(5):539-41. PubMed ID: 18669440
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain cancer. A viral link to glioblastoma?
    Miller G
    Science; 2009 Jan; 323(5910):30-1. PubMed ID: 19119195
    [No Abstract]   [Full Text] [Related]  

  • 4. Dendritic cell vaccines to combat glioblastoma.
    Wheeler CJ
    Expert Rev Neurother; 2010 Apr; 10(4):483-6. PubMed ID: 20367199
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
    Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
    Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?
    Van Gool S; De Vleeschouwer S
    Expert Rev Neurother; 2012 Oct; 12(10):1173-6. PubMed ID: 23082731
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
    Ferguson SD; Srinivasan VM; Ghali MG; Heimberger AB
    Immunotherapy; 2016; 8(4):413-23. PubMed ID: 26973123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First results on the DCVax phase III trial: raising more questions than providing answers.
    Wick W; van den Bent MJ
    Neuro Oncol; 2018 Sep; 20(10):1283-1284. PubMed ID: 30137551
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
    Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
    Front Immunol; 2018; 9():727. PubMed ID: 29910795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [II. Autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma].
    Maruyama T; Muragaki Y; Ishikawa E; Nitta M; Saito T; Ohno T; Iseki H; Okada Y
    Gan To Kagaku Ryoho; 2015 Jun; 42(6):683-6. PubMed ID: 26242005
    [No Abstract]   [Full Text] [Related]  

  • 12. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
    De Vleeschouwer S; Fieuws S; Rutkowski S; Van Calenbergh F; Van Loon J; Goffin J; Sciot R; Wilms G; Demaerel P; Warmuth-Metz M; Soerensen N; Wolff JE; Wagner S; Kaempgen E; Van Gool SW
    Clin Cancer Res; 2008 May; 14(10):3098-104. PubMed ID: 18483377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.
    Reap EA; Suryadevara CM; Batich KA; Sanchez-Perez L; Archer GE; Schmittling RJ; Norberg PK; Herndon JE; Healy P; Congdon KL; Gedeon PC; Campbell OC; Swartz AM; Riccione KA; Yi JS; Hossain-Ibrahim MK; Saraswathula A; Nair SK; Dunn-Pirio AM; Broome TM; Weinhold KJ; Desjardins A; Vlahovic G; McLendon RE; Friedman AH; Friedman HS; Bigner DD; Fecci PE; Mitchell DA; Sampson JH
    Cancer Res; 2018 Jan; 78(1):256-264. PubMed ID: 29093005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
    Batich KA; Reap EA; Archer GE; Sanchez-Perez L; Nair SK; Schmittling RJ; Norberg P; Xie W; Herndon JE; Healy P; McLendon RE; Friedman AH; Friedman HS; Bigner D; Vlahovic G; Mitchell DA; Sampson JH
    Clin Cancer Res; 2017 Apr; 23(8):1898-1909. PubMed ID: 28411277
    [No Abstract]   [Full Text] [Related]  

  • 15. Hope and challenges for dendritic cell-based vaccine therapy for glioblastoma.
    Nakano I; Chiocca EA
    World Neurosurg; 2012; 77(5-6):633-5. PubMed ID: 22120228
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapy trials for glioblastoma multiforme: promise and pitfalls.
    Yong RL; Lonser RR
    World Neurosurg; 2012; 77(5-6):636-8. PubMed ID: 22120230
    [No Abstract]   [Full Text] [Related]  

  • 17. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
    Yu JS; Wheeler CJ; Zeltzer PM; Ying H; Finger DN; Lee PK; Yong WH; Incardona F; Thompson RC; Riedinger MS; Zhang W; Prins RM; Black KL
    Cancer Res; 2001 Feb; 61(3):842-7. PubMed ID: 11221866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
    Schaller TH; Sampson JH
    Expert Rev Vaccines; 2017 Jan; 16(1):27-36. PubMed ID: 27500911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of inflationary cytomegalovirus-specific memory T cells on anti-tumour immune responses in patients with cancer.
    Luo XH; Meng Q; Rao M; Liu Z; Paraschoudi G; Dodoo E; Maeurer M
    Immunology; 2018 Nov; 155(3):294-308. PubMed ID: 30098205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.
    Curry WT; Gorrepati R; Piesche M; Sasada T; Agarwalla P; Jones PS; Gerstner ER; Golby AJ; Batchelor TT; Wen PY; Mihm MC; Dranoff G
    Clin Cancer Res; 2016 Jun; 22(12):2885-96. PubMed ID: 26873960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.